<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00198276</url>
  </required_header>
  <id_info>
    <org_study_id>EU-CCBE-2003</org_study_id>
    <nct_id>NCT00198276</nct_id>
  </id_info>
  <brief_title>Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutaneous and Subcutaneous Cancer</brief_title>
  <official_title>An Open-Label Study Using the MedPulser Electroporation System to Treat Cutaneous and Subcutaneous Foci of Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inovio Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inovio Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to study the safety and efficacy of MedPulser Electroporation&#xD;
      with bleomycin treatment of cutaneous and subcutaneous foci of cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Electroporation therapy (EPT) is a tumor-specific ablative treatment modality with the&#xD;
      potential to manage local tumors without the potentially undesirable side effects of systemic&#xD;
      chemotherapy agents or radiotherapy. Surgical resection of cutaneous lesions may lead to&#xD;
      significant organ dysfunction and/or permanent disfigurement requiring reconstructive surgery&#xD;
      (i.e. nose, eye area, ears, medial canthus, nasolabial fold, lip, scalp, etc.). In contrast,&#xD;
      electroporation therapy may offer equivalent disease control to conventional surgery with a&#xD;
      lessened need for reconstructive surgery.&#xD;
&#xD;
      The ability to ablate local cutaneous lesions with the MedPulserÂ® System when used in&#xD;
      conjunction with intralesional Bleomycin is an important new treatment for the local&#xD;
      management of recurrent Basal Cell Carcinoma (BCC), recurrent Squamous Cell Carcinoma (SCC),&#xD;
      Melanoma, Adenocarcinoma (i.e. local recurrence of breast cancer), Merkel Cell Carcinoma and&#xD;
      Cutaneous Lymphoma and other solid tumors with symptomatic subcutaneous recurrences and&#xD;
      provides an alternative treatment option to subjects who:&#xD;
&#xD;
        1. have failed standard treatments; or who&#xD;
&#xD;
        2. are unwilling or unsuitable to undergo conventional surgical excision or radiation.&#xD;
&#xD;
      EPT with Bleomycin spares normal tissue and its use in local disease management may preserve&#xD;
      organ function and/or appearance relative to surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>MedPulser Electroporation with Belomycin</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local tumor control</measure>
    <time_frame>6 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacoeconomic factors (e.g. hospital costs, extent of medical interventions, medication use)</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MedPulser instrument and applicator performance</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Bleomycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bleomycin 4.0 U/mL at dose of 1 U/cm^3 of treatment area; Medpulser EP</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>MedPulser Electroporation with bleomycin</intervention_name>
    <description>The MedPulser device will be used in combination with Bleomycin Sulfate injection around the tumor area in a concentration of 1 U/ml per cm3 of tumor treatment area.</description>
    <arm_group_label>Bleomycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The presence of recurrent SCC, recurrent BCC, melanoma, adenocarcinoma (i.e., local&#xD;
             recurrence of breast cancer), merkel cell carcinoma, cutaneous lymphoma, other&#xD;
             subcutaneous solid tumors, or primary cutaneous tumors must be confirmed by&#xD;
             histological examination of a tissue (e.g., biopsy) sample obtained within 1 month&#xD;
             prior to a patient signing the informed consent form for the study.&#xD;
&#xD;
          2. Total volume of disease treated will require a dose of bleomycin sulfate less than 80&#xD;
             units.&#xD;
&#xD;
          3. Tumors and margins must be completely accessible to intralesional bleomycin injections&#xD;
             and the EPT applicator electrodes.&#xD;
&#xD;
          4. Age: 18 years or older.&#xD;
&#xD;
          5. Male or female.&#xD;
&#xD;
          6. Men and women of childbearing potential must be using physician prescribed&#xD;
             contraceptive methods while undergoing protocol related therapy.&#xD;
&#xD;
          7. Baseline performance status: ECOG 0-2&#xD;
&#xD;
               -  Grade 0: Fully active, able to carry on all pre-disease performance without&#xD;
                  restriction.&#xD;
&#xD;
               -  Grade 1: Restricted in a physically strenuous activity but ambulatory and able to&#xD;
                  carry out work of a light or sedentary nature, e.g., light house work, office&#xD;
                  work.&#xD;
&#xD;
               -  Grade 2: Ambulatory and capable of all self-care, but unable to carry out any&#xD;
                  work activities. Up and about more than 50% of waking hours.&#xD;
&#xD;
          8. Life expectancy of at least 6 months.&#xD;
&#xD;
          9. Sign a written Informed Consent prior to receiving any study procedures or treatments.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with tumors suspected of involving a 50% or greater encasement of a blood&#xD;
             vessel as measured by magnetic resonance imaging (MRI) or computed tomography (CT)&#xD;
             scan.&#xD;
&#xD;
          2. Subjects with tumors having bone invasion.&#xD;
&#xD;
          3. Subjects with hypersensitivity to bleomycin.&#xD;
&#xD;
          4. Subjects who have received or will exceed a total lifetime dose of bleomycin greater&#xD;
             than 400 units.&#xD;
&#xD;
          5. Subjects with a significant history of emphysema or pulmonary fibrosis.&#xD;
&#xD;
          6. Subjects with indwelling cardiac pacemakers who cannot tolerate a period with&#xD;
             pacemaker turned off.&#xD;
&#xD;
          7. Subjects with a history of uncontrolled cardiac arrhythmia.&#xD;
&#xD;
          8. Women who are pregnant, or are nursing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Goldfarb, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Inovio Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inovio Biomedical Corporation</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <disposition_first_submitted>April 24, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>April 24, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 3, 2013</disposition_first_posted>
  <last_update_submitted>September 27, 2017</last_update_submitted>
  <last_update_submitted_qc>September 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>cutaneous</keyword>
  <keyword>subcutaneous</keyword>
  <keyword>MedPulser</keyword>
  <keyword>bleomycin</keyword>
  <keyword>electroporation</keyword>
  <keyword>Cutaneous or subcutaneous cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bleomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

